This study examined the involvement of the STAT3 signaling pathway in obesity-related airway inflammation and its potential as a therapeutic target. The correlation between obesity and asthma has become increasingly evident with the rising prevalence of obesity among children. Obesity-associated asthma is classified as an atypical form of asthma, primarily mediated by neutrophils and Th17 cells. STAT3 is integral to the regulation of immune responses and inflammatory processes, suggesting that STAT3 inhibitors could represent a novel therapeutic approach for managing obesity-associated airway inflammation. Future research should aim to elucidate the role of STAT3 across various asthma phenotypes and investigate specific inhibitors targeting the STAT3 signaling pathway to enhance the management and prognosis of obesity-associated asthma.